IBRX Share Price Performance
US$0
-2.74 (-100.00%)
Price US$0
Fair ValueUS$13.00
Share Pricen/a
Seeking Alpha • Sep 03
ImmunityBio, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 133 Fair Values set on narratives written by author
IBRX Community Narratives
AN
Fair Value
·Fair Value US$13 35.6% undervalued intrinsic discount
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
2users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value
·Fair Value US$15 44.2% undervalued intrinsic discount
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$12 30.3% undervalued intrinsic discount
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
ImmunityBio
44.2% undervalued intrinsic discount
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
View narrativeAN
Updated 24 Jul
ImmunityBio
35.6% undervalued intrinsic discount
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
View narrativeAN
Updated 26 Jun
ImmunityBio
30.3% undervalued intrinsic discount
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
View narrativeAN
Updated 10 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside
Fair Value: US$15 44.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Fair Value: US$12 30.3% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Fair Value: US$13 35.6% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ImmunityBio, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.94
- 99.34%
- -598.56%
- -113.7%
About IBRX
- Founded
- n/a
- Employees
- 688
- CEO
- WebsiteView website
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
